Key Highlights

  • Avere pre‑merger shareholders will control a significant portion of the post‑merger enterprise.
  • Individual holders may be limited to a maximum ownership, defaulting to a lower percentage if no election is made.
  • The first step merges a NextCure subsidiary with Avere, making Avere a direct subsidiary of the parent company.

NextCure, Inc. (NASDAQ: NXTC) filed a formal agreement to combine with Avere Therapeutics, Inc. The merger will occur through a two‑entity structure that consolidates Avere into a wholly owned subsidiary of NextCure, followed by a second step that merges the subsidiary into a different NextCure entity.

Transaction Structure

The first step merges a NextCure subsidiary with Avere, making Avere a direct subsidiary of the parent company. Immediately afterward, Avere merges into a second NextCure subsidiary, which emerges as the surviving entity. This dual‑merger design aims for a tax‑efficient reorganization framework, which is typical in the biotechnology sector where companies like NextCure and Avere Therapeutics operate.

Share Exchange Mechanics

Each Avere share will be exchanged for NextCure shares based on a formula disclosed in the agreement. Holders whose total holdings would exceed a specified percentage will receive pre‑funded warrants for the excess portion; if no election is filed, the cap defaults to a lower percentage. The arrangement also converts outstanding Avere options, restricted stock units and warrants into comparable NextCure instruments, which is a common practice in mergers and acquisitions.

Tax Treatment

The parties aim for the transaction to qualify as a tax‑efficient reorganization. This classification would permit the exchange of equity without immediate tax liability for shareholders, subject to standard rules.

Dilution Impact

Following the merger, the equity distribution will heavily favor Avere’s pre‑merger owners, who are projected to own a significant portion of the combined company, with pre-Merger Avere stockholders owning approximately 98.11% and pre-Merger NextCure stockholders owning approximately 1.89%.

Corporate Actions

Prior to closing, NextCure’s board will accelerate vesting of all outstanding equity awards. The company also plans to seek shareholder approval for a charter amendment that will rename the combined firm to Avere Therapeutics, Inc. And may include a reverse stock split if required. This is a standard procedure in mergers, where the resulting company may need to restructure its shares.

Shareholder Approval

The merger will be presented to NextCure shareholders via a proxy statement filed on Form S‑4. The filing includes proposals to issue new shares, amend the charter, and possibly relocate the corporate domicile, all of which require majority support at the upcoming meeting. In the biotechnology sector, such mergers and acquisitions require careful planning and approval from shareholders to ensure a smooth transition.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.